美国 · SEC FORM 4
ARS Pharmaceuticals, Inc.
SPRY · Nasdaq · CIK 0001671858 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
3 同一窗口内观察到的 Form 4 交易行
2 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-03-27 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 21,190,047
- 上期报告
- 23,073,209
- 日均成交量
- 1,316,280
- 回补天数
- 16.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-03-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 505,954 | USD 9.79 | USD 4,953,290 | SEC 申报 ↗ |
| 2024-03-26 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 457,745 | USD 9.55 | USD 4,371,465 | SEC 申报 ↗ |
| 2024-03-25 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 437,600 | USD 9.06 | USD 3,964,656 | SEC 申报 ↗ |
| 2023-09-29 | Fitzpatrick Alexander A | 买入 (P) | Common Stock | 46,258 | USD 3.78 | USD 174,855 | SEC 申报 ↗ |
| 2023-09-28 | Fitzpatrick Alexander A | 买入 (P) | Common Stock | 40,000 | USD 3.62 | USD 144,800 | SEC 申报 ↗ |
| 2023-09-21 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 2,700,000 | USD 3.03 | USD 8,183,526 | SEC 申报 ↗ |
| 2023-08-29 | Thompson Peter A. | 买入 (P) | Common Stock | 500,000 | USD 6.20 | USD 3,100,000 | SEC 申报 ↗ |
| 2023-08-29 | ORBIMED ADVISORS LLC; ORBIMED CAPITAL LLC; OrbiMed Capital GP VI LLC | 买入 (P) | Common Stock | 500,000 | USD 6.20 | USD 3,100,000 | SEC 申报 ↗ |
| 2023-08-29 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 3,750,000 | USD 6.20 | USD 23,250,000 | SEC 申报 ↗ |
| 2022-11-29 | Scott Kathleen D. | 买入 (P) | Common Stock | 8,250 | USD 6.24 | USD 51,480 | SEC 申报 ↗ |
| 2021-11-15 | ROOT JONATHAN D | 买入 (P) | Common Stock | 2,014 | USD 8.85 | USD 17,824 | SEC 申报 ↗ |
| 2021-03-03 | ROOT JONATHAN D | 买入 (P) | Common Stock | 350 | USD 52.07 | USD 18,224 | SEC 申报 ↗ |
| 2020-12-08 | Hawkinson Russ | 买入 (P) | Common Stock | 200 | USD 21.00 | USD 4,200 | SEC 申报 ↗ |
| 2020-12-08 | Thompson Peter A. | 买入 (P) | Common Stock | 1,190,477 | USD 21.00 | USD 25,000,017 | SEC 申报 ↗ |
| 2020-12-08 | Schroeder Thilo | 买入 (P) | Common Stock | 238,096 | USD 21.00 | USD 5,000,016 | SEC 申报 ↗ |
Form 4 申报证据
10 transaction lines in the latest 365-day window; 341 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | Karas Eric | 卖出 (S) | Common Stock | 25,000 | USD 10.00 | USD 250,000 | SEC 申报 ↗ |
| 2026-06-12 | Karas Eric | 期权行权／转换 (M) | Common Stock | 25,000 | USD 1.50 | USD 37,500 | SEC 申报 ↗ |
| 2026-06-12 | Fitzpatrick Alexander A | 卖出 (S) | Common Stock | 3,355 | USD 10.00 | USD 33,550 | SEC 申报 ↗ |
展开近期 Form 4 证据 (8 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | Karas Eric | 卖出 (S) | Common Stock | 25,000 | USD 10.00 | USD 250,000 | SEC 申报 ↗ |
| 2026-06-12 | Karas Eric | 期权行权／转换 (M) | Common Stock | 25,000 | USD 1.50 | USD 37,500 | SEC 申报 ↗ |
| 2026-06-12 | Fitzpatrick Alexander A | 卖出 (S) | Common Stock | 3,355 | USD 10.00 | USD 33,550 | SEC 申报 ↗ |
| 2025-11-13 | Dorsey Brian | 卖出 (S) | Common Stock | 21,828 | USD 8.71 | USD 190,122 | SEC 申报 ↗ |
| 2025-11-13 | Dorsey Brian | 期权行权／转换 (M) | Common Stock | 21,828 | USD 0.64 | USD 13,970 | SEC 申报 ↗ |
| 2025-11-12 | Shah Pratik | 赠与 (G) | Common Stock | 350,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-12 | Chakma Justin | 卖出 (S) | Common Stock | 166,380 | USD 8.87 | USD 1,475,627 | SEC 申报 ↗ |
| 2025-11-12 | Chakma Justin | 期权行权／转换 (M) | Common Stock | 30,000 | USD 0.84 | USD 25,200 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SPRY |
| CIK | 0001671858 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 341 transaction lines from 2020-12-08 to 2026-06-12 24 P purchase lines · 199 S sale lines · 118 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.